Brief: GeNeuro Phase 2b Multiple Sclerosis study recruitment reaches halfway mark ahead of schedule

Geneuro SA

14/09/2016 06:31

Sept 14 (Reuters) - GeNeuro  GNRO.PA : 
    * Phase 2b Multiple Sclerosis study recruitment reaches halfway mark ahead of schedule  
    * The double-blind, placebo-controlled study, CHANGE-MS is slated to enroll 260 patients in 
69 clinical centers in 13 European countries 
    * CHANGE-MS Phase 2b study is fully funded through GeNeuro`s 362.5 million euros ($406.76 
million) partnership with Servier signed in 2014 
    * Primary data read-out confirmed in Q4 2017 
    * Over 130 of 260 patients enrolled 
 
Source text for Eikon:  ID:nBw7KjBH6a  
Further company coverage:  GNRO.PA  
 
($1 = 0.8912 euros) 
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 698 3920;))